Clinical trial InMind
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma
| Organ | Lymphoma |
|---|---|
| Trial status | Trial closed for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Incyte Corporate |
| EudraCT Identifier | 2020-004407-13 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT04680052 |
| Inclusion criteria | >18yearsR/R FL and MZLFL Grade 1-3a, MZLECOG 0-2> Prior anti-CD20 Therapy |
| Last update |